AstronauTx
David Reynolds is the Founder & Non-Executive Director at AstronauTx and the CEO of LoQus23 Therapeutics Ltd, a biotech company focusing on DNA damage repair pathways for treating neurodegenerative diseases. Along with their roles at SV Health Investors and UCL as a Visiting Professor, David has a wealth of experience in leadership positions at companies like Pfizer and H. Lundbeck A/S. David holds a BA and PhD in Natural Sciences from the University of Cambridge.
This person is not in any teams
This person is not in any offices
AstronauTx
AstronauTx is at the forefront of a novel approach to treating neurodegenerative diseases. We have a unique portfolio of small-molecule therapeutics to restore dysregulated physiology to both improve symptoms and modify disease.